Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 7, 2006

View Archived Issues

Vical begins phase II study of DNA vaccine against CMV

Dr. Reddy's and Argenta collaborate on novel treatment for COPD

Avantogen and Innovate Oncology merge key oncology program

Altea and Teikoku Seiyaku sign Parkinson's transdermal patch agreement in Japan

Samaritan inlicenses drugs for mitochondrial disorders

Levulan BLU-U reduces acne lesions in phase II study

Elan updates progress

Antitumor and antiangiogenic potential of the phytochemical sulforaphane

In vitro and in vivo anticancer activity of KP-772

Targeting bombesin/GRP receptor pathways for sepsis

Enrollment completed in phase III chronic low back pain study of bicifadine

Halozyme begins study of subcutaneous morphine with Hylenex

Chromos Molecular Systems acquires Targeted Molecules

InterMune discontinues Actimmune ovarian cancer study

Zactima granted fast track designation for medullary thyroid carcinoma

Acuity studies Cand5 for wet AMD and diabetic macular edema

Ecopia cleared for Canadian phase I study of ECO-4601 in cancer patients

IND approved for phase I study of abiraterone acetate in advanced prostate cancer

Additional clinical responses seen in phase II talabostat studies

Androxal may restore normal testosterone level in testosterone deficient men

RotaTeq receives FDA approval

Recent Japan Tobacco patents disclose novel analgesic agents

Novel therapeutics for neurological disorders reported in recent patent literature

High intake of antioxidants may reduce the risk of AMD

Angiotensin II receptor antagonists evaluated for the treatment of hepatic fibrosis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...